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ABSTRACT
The effects of aspirin, vitamin B2 and warfarin as potential blockers of the ruthenium binding sites in
HSA were investigated through UV/visible, circular dichroism (CD), fluorescence spectroscopy and the
inductively coupled plasma-atomic emission spectroscopy ICP(AES). The studies on the interactions of
several biologically relevant molecules with HSA have shown that drugs like aspirin or warfarin may
strongly influence the interaction of serum protein with anticancer drugs. It can derive from the influence of
the drug on protein conformation or binding close to binding site of anticancer drug. Aspirin, vitB2 and
warfarin bind to IIA subdomain leading to partial blocking of the ruthenium binding site in HSA.
Keywords: Ruthenium(Ill); Human Serum Albumin; Circular dichroism, Fluorescence quenching; Aspirin;
Warfarin; Vitamin Bl2
INTRODUCTION
A full understanding of the modes of action of the metal-based antitumoral drugs requires the detailed
study of their interactions with all possible biological targets including amino acids, hormones, peptides and
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proteins. Albumin is the most abundant plasma protein and the interaction with metal anticancer drugs may
have a major influence on drug pharmacology and efficacy.
A number of Ru(III) complexes exhibit antitumor activities in animal models /1/. Two anticancer
ruthenium (III) complexes, with imidazole and indazole ligands are highly active compared to other
ruthenium(ill) compounds. Both of these complexes show excellent antitumor activity in various animal
models/2/. The most promising complex is Hlnd[RuInd2Cl4 abbrev. Ru-ind (scheme 1) which is far less
toxic in long term application than the imidazole analogue/3/. This has inspired considerable interest in the
study of the biochelical behavior of the Ru-ind compounds including their interactions with serum proteins,
which, are the primary target molecules, when metal compound is administered intravenously /4/. The
preferred binding sites for the Ru(lll) complexes are at histidyl residues of the protein, presumably following
the loss of one or more of the chloride ligands/5/. The major amount of ruthenium species (80-90 %) is
bound to albumin and a much smaller amount to transferrin/4/. Apotransferrin may act as a natural carrier of
the ruthenium drug and this has caused strong interest in the studies on Ru(iIl)-apotransferrin system/6, 7/.
The coordination of ruthenium to apotransferrin can be used to enhance tumor uptake, since neoplastic cells,
especially those in rapidly growing tumors, have a high iron requirement and display a large number of
transferrin receptors on their membrane surfaces. Furthermore, it has been demonstrated that the
apotransferrin-bound Ru-ind complex exhibits a significantly higher antitumor activity against human colon
cancer cells when compared with the "free" species/4/. In contrast ruthenium-albumin bound species have no
significant antitumor activity.
Scheme 1: Schematic representation of Hlnd[Rulnd.Cl4] complex
Interactions with albumin could be of critical importance for understanding the Ru(lll) toxicity and its
distribution within the organism. This metal-species binding would lead to altered protein conformation and
142L. 7)ynda-Lemiesz and M. Luczko:ki Bioinorganic Chemistry andApplications
changes in biological activity of the protein/8, 9/. Human serum albumin (HSA), is a single-chain 66 kDa
protein, which is largely c-helical, and consists of three structurally homologous domains that assemble to
form a heart-shaped molecule. Each domain is a product of two subdomains, which are predominantly helical
and extensively cross-linked by several disulfide bridges/I0/. Its amino-acid sequence contains a total of 17
disulphide bridges, one free thioi (Cys 34) and a single tryptophan (Trp 214). Albumin is known to bind and
transport many ligands, including fatty acids, amino acids, steroids, metal ions, and a variety of
pharmaceuticals/! 1, 12/. The principal regions of ligand binding sites of albumin are located in hydrophobic
cavities in subdomains IIA and IIIA, which exhibit similar chemistry. The binding locations have been
determined crystallographically for several ligands. The IliA subdomain is the most active in accommodating
many ligands, as for example, digitoxin, ibuprofen and tryptophan. Aspirin show nearly equal distributions
between binding sites located in IIA and III A subdomains, while warfarin occupies a single site in IIA/12/.
The high-affinity site for bilirubin has been isolated in domain II/13/, and the principal binding site for long-
chain fatty acids has been shown to occupy the domain III/14/. The likely location of the multi-metal site in
human albumins is thus the area of contact of domains and II/15/. Aquacobalamin (aqua-B2) binds to
albumin via imidazole groups ofhistidyi residues located in IIA and Ilia subdomain/16/.
Ligand binding to one domain induces distinct conformational changes in the other domain, as both
subdomains share a common interface. Thus, the binding of particular drug molecule to serum albumin may
change considerably binding abilities of HSA towards other molecules. A previous study/9/has shown that
albumin can specifically bind up to four moles of the Ru-indazole complex. In this work the effects of
aspirin, vitamin -B2 and warfarin as potential blockers of the ruthenium binding sites in HSA were
investigated.
EXPERIMENTAL
Materials
Human serum albumin and sodium salicylate were obtained from Fluka Chem.Co. Aspirin, warfarin,
Sephadex G-25 and apo-transferrin were purchased from Sigma, aquo-Bi2 from Serva. HSA concentration
was determined by absorption spectrum, taking the absorbance of a lmg/cm solution at 280 nm as 0.55/17/.
Aspirin acetylated HSA was prepared according to the procedure of Pincard et al. /18/Trans-indazolium
bisindazole-tetrachlororuthenate(IIl) was synthesized as described earlier /19/ and was used in all
experiments from a freshly prepared 5x10-4M aqueous solution. In all the experiments a. physiological buffer
was used so that the final concentrations were 0.004 M NaH2PO4, 0.1M NaCI and 0.025M NaHCO3, pH 7.4.
Methods
Absorption spectra were recorded on a BECKMAN DU-650 spectrophotometer, and CD spectra on a
JASCO J-715 spectropolarimeter. CD spectra were recorded over the range of 200-250 and 250-360 nm,
300-600 rim, using 0.! and 1.0 cm ceils respectively. Fluorescence measurements were carried out on an
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SLM AMINco SPF-500 spectrofluorimeter with the excitation and emission wavelength set at 335 and 378
nm (warfarin).
The assays of ruthenium bounded per mol of HSA were performed with a Spectrometer 3410 (Inductively
Couplet Plasma-Atomic Emission Spectroscopy, ICP-AES). The protein fractions bound with ruthenium
complex were separated by gel-filtration chromatography on Sephadex G-25 column. The ruthenium content
in the selection fraction was determined by the ICP method.
RESULTS AND DISCUSSION
Binding of Ru(lll) indazole species to albumin has a strong impact on protein structure and physiological
functions, but essentially this interaction may have a major influence on drug pharmacology and efficacy and
plays an important role in the metabolism of this anticancer agent.
Transferrin may act as a moderately selective carrier for HInd[RuIndzCl4] complex into tumor cells. Ru-
Tf has a substantially greater uptake into tumors, probably because of the unusually large number of
transferrin receptors on the surface of cancer cells. The potential of using transferrin conjugates for selective
drug delivery to tumor tissue should be seen in light of the natural transferrin cycle and iron metabolism.
Structural differences between transferrin, apotransferrin and Ru(III)-apotransferrin (Fig. 1) are very small
and for that reason, transferrin might be able to act as a selective drug delivery system for antitumor
ruthenium complexes.
The albumin structure (Fig. 2)/20/is predominantly et-helical. Approximately, 67% of lISA is helical,
the number of helices in the structure is 28 /12/. CD spectra of HSA exhibit two negative bands in the
ultraviolet region at 209 and 220 nm characteristic for an c-helical structure of protein. The binding of
ruthenium complex to HSA decreases both of these bands /9/. This clearly indicates the changes in the
protein secondary structure.
Aspirin acetylated albumin
The two lysine residues on albumin are highly reactive toward tribenzenosulfonates and aspirin. At low
aspirin concentrations, a single lysine residue of HSA is selectively acetylated by aspirin. Walker/21/has
identified the predominant site of acetylation as lysine 199. The binding locations determined
crystallographically /12/ indicated that aspirin shows nearly equal distributions between binding sites located
in IIA and III A subdomains. CD spectroscopy measurements show (Fig. 3), that acetylation of albumin at
low aspirin concentrations results in marked conformational changes of the protein. Further conformational
changes in the HSA structure induced by ruthenium coordination indicate that aspirin is not able to prevent
ruthenium binding. However, it may induce some conformational changes and local perturbations at the
ruthenium binding sites.
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UV CD spectra of native transferrin (solid line), native apotransferrin (dashed line) and native
apotransferrin incubated with HInd[RulndzCl4] complex (dotted line) after 24 hours of reaction
running at 37C. C,pot,..,,sre,-,-i,, 2 * 10
-6 M; molar ratio Ru(III)/apotransferrin 2:1
Fig. 2" Crystal structure of Human Serum Albumin/20/.
145Vol. 1, No. 2, 2003 hnpact ofPotential Blockers on Ru(lll) Complex Binding to
Human Serum Albumin
0,0
E -0,2
-0,:3
-0,5
200 210 220 230 240 250
Wavelength (nm)
Fig. 3: UV CD spectra of native HSA (solid line), acetylated HSA (dashed line) and acetylated HSA
incubated with HInd[RulndzCl4] complex (dotted line) after 24 hours of reaction running at 37C.
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.6 M, CRu-i,ld 1.6 * 10-SM
Warfarin
Warfarin is one of the best characterized drugs as far as the binding sites in HSA are concerned/22/. Site
is located in subdomain IIA near Trp-214/23/. Warfarin has a weak fluorescence at 378 nm when excited at
335 rim, and the addition of HSA induced an increase in fluorescence intensity when warfarin binds to a
single site in the protein /24/. Binding of ruthenium(III) complexes to HSA has an influence on warfarin
binding site in albumin/9/. Hlnd[RuInd2Cl4] causes sevenfold decrease of a relative fluorescence intensity at
335 nm. However, the interaction of ruthenium compound with albumin already preincubated with warfarin
quenches only slightly the intensity of this band (Fig. 4). This may suggest that HInd[RulndzCl4] and
warfarin compete for the binding sites located at Trp24 residue and that binding of warfarin to HSA protects
the binding of Hlnd[Rulnd2Cl4] to the protein.
The changes in the CD spectra (Fig. 5) confirm the results achieved in fluorescence measurements. The
characteristic shape of the spectra for HSA preincubated with HInd/RulndzCl4/ is distinctly different from
that of the native HSA, while the shape of the spectra obtained for HSA incubated prior with warfarin and
then with ruthenium compound is almost the same although with decreased bands intensities.
Aquacobalamin (aqua-Bz)
16.5% of the serum B2 is bound to albumin via imidazole groups of histidyl residues located in IIA and
IliA subdomain/25/. Binding of aquacobalamin to HSA can be easily monitored by spectroscopic methods,
especially the CD spectra. The CD spectra of aqua-form of vitamin Bj_ bound to HSA differ considerably
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Fig. 4: Relative fluorescence intensity changes of warfarin with ruthenium treated HSA after 24 hours of
reaction running at 37C. HSA-warfarin (solid line), HSA-warfarin+ HInd[RuIndzCl4] (dashed line),
HSA-HInd[RulndzCl4]+warfarin (dotted line), warfarin (short-dotted line); qSA 4* 10
8* 10
-5 M, molar ratio Ru(III)/HSA 2"1 excitation 2= 335 rim, emission 2 378 nm
HSAWarf )
HSAWarf-Ru
NSARu-Warl
-4-
-5
260 280 300 320 340 360
Wavelength (nm)
Fig. 5: Effect of Ru(lll)-indazole on the vsole CO spectrum of HSA-warfarin. HSA-warfarin (solid line),
HSA-warfarin+ Hlnd[Rulnd2Cl4] (dashed line), HSA-Hlnd[Rulnd2C14]+warfarin (dotted line); c-sa
4* 10
.5 M, Cw,,-r,,.i, 8* 10
5 M, molar ratio Ru(III)/HSA 2:1
from those of the free vitamin (see Fig. 6). The band intensities increase and the. single band at 483 nm
appears as a consequence of the complex formation. HInd[RuIndzC14] may influence aquacobalamin binding
by partial blocking of its binding site or inducing conformational changes leading to decreased affinity of
HSA to the vitamin.
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Fig. 6: Effect of Ru(lll)-indazole on the visible CD spectrum of HSA-B2. HSA-B2 (solid line), HSA-B12+
Hlnd[Rulnd2Cl4] (dashed line), HSA-Hlnd[Rulnd2Cla]+B2 (dotted line), B2 (short-dotted line);
CSA 4* 10
.5 M, cB2 8* 10
.5 M, molar ratio Ru(III)/HSA 2:1
CONCLUSIONS
The interaction of anticancer drugs with blood constituents, particularly with serum albumin may have a
major influence on drug pharmacology and efficacy/26/.
As already shown/4/, about 80% of ruthenium complexes bind to HSA and a much smaller amount to
transferrin. It has been demonstrated that the apotransrerrin-bound ruthenium complex exhibits a
significantly higher antitumor activity against human colon cancer cells when compared with the "free"
species. In contrast ruthenium-albumin bound species have no significant antitumor activity.
It is known that the binding of a particular drug molecule to serum albumin may change considerably the
binding abilities of HSA towards other molecules. The relatively neutral drugs such as aspirin or vitamin Bz
and warfarin, a widely used anticoagulant, which is 99% bound to protein, bind to llA subdomain in HSA
leading to partial blocking of ruthenium binding site. A previous study/9/has shown that native albumin can
specifically bind up to four moles of the Ru(lll)-indazole complex. After modification of HSA by warfarin,
vitB, and aspirin the ruthenium content decreases to 1.6, 1.65 and 1.2 moles per tool of the protein,
respectively (Fig.7). Warfarin, vitB2 and aspirin may influence ruthenium binding by partial blocking of its
binding site or inducing conformational changes leading to decreased affinity of HSA to the Ru(lli)-indazole
complex.
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Fig. 7: The binding of ruthenium complex to HSA, after modification by warfarin, vitamin B!2 and aspirin.
The protein fractions bound with ruthenium were separated by gel-filtration chromatography. Ru
contents in selection fractions were determined using the ICP(AES) method.
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